Vaxcyte, Foster City, CA, USA
GROUP A STREP CARBOHYDRATE ANTIGEN
Carbohydrate conjugate vaccine
Vaxcyte, formerly SutroVax, is developing an innovative vaccine to prevent pharyngitis (‘Strep Throat’), which can range from minor illness to a very serious and deadly disease. Currently, no vaccine exists to prevent pharyngitis infections, which are caused by Group A Streptococcus (GAS) bacteria. The Vaxcyte vaccine is composed of GAS carbohydrate antigen coupled to an immunogenic protein carrier using the company’s site-specific conjugation technology. The vaccine has been developed to avoid triggering an immune response that can adversely affect cardiac or brain tissue, which had been seen with earlier vaccines. The discovery of the GAS antigen was made at the University of California at San Diego. Vaxcyte has a license to the technology. The vaccine is being developed for use in all parts of the world. Part of CARB-X’s award will come from funds provided by the UK Government’s Global AMR Innovation Fund (GAMRIF), an Official Development Assistance (ODA) fund which supports projects that promote the welfare and economic development of low-and middle-income countries (LMICs).
Current Development Stage: Pre-clinical
CARB-X Investment: Initial investment of up to $1.64m with potential option payments up to $13.4m
Initial CARB-X Investment Date: June 1, 2019
Read their Spotlight on Science